Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (NASDAQ: TNGX) is a precision oncology company focused on discovering and developing targeted therapies for patients with genetically defined cancers. The company's website is located at tangotx.com.

Tango leverages its proprietary target discovery platform and synthetic lethality approach to identify novel disease-relevant targets and develop small molecule inhibitors designed to selectively kill cancer cells harboring specific genetic alterations while sparing normal cells. The company's core strategy centers on exploiting pairs of genes or pathways in which one is inactivated by a tumor-specific alteration and the other is inhibited pharmacologically, thereby maximizing therapeutic benefit while minimizing toxicity to healthy tissue.

The company's clinical pipeline is anchored by two MTAP-deleted selective PRMT5 inhibitors. Vopimetostat (TNG462) is being evaluated as both a monotherapy and in combination with RAS inhibitors for non-CNS cancers, particularly pancreatic and lung cancer. TNG456 is a next-generation, brain-penetrant PRMT5 inhibitor focused on central nervous system cancers, including glioblastoma. The company is also developing TNG260, a first-in-class CoREST inhibitor targeting STK11 mutant lung cancer, and TNG961, a molecular glue development candidate targeting HBS1L for degradation in FOCAD-deleted and MTAP-deleted cancers.

Tango's addressable market encompasses approximately 60,000 annual patients in the United States across its primary development indications, with an additional 7,000 patients annually for glioblastoma. The company does not own or operate manufacturing facilities and relies on third-party contract development and manufacturing organizations for production of its investigational products.

The company maintains an intellectual property portfolio consisting of multiple patent families covering its PRMT5 and CoREST inhibitors, with expected patent expirations ranging from 2039 to 2045. Tango was formed through a merger with BCTG Acquisition Corp. in August 2021 and operates as a smaller reporting company within the biopharmaceutical industry.